AZ-CAMELBACK-OWNER
One Can Imagine. That philosophy is the driving force of the experienced leadership team that’s responsible for introducing One Camelback, an innovative live-play community that’s taking shape at the hottest intersection in greater Phoenix, according to real estate and growth experts at Urban Land Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005151/en/
“Arizona hasn’t seen anything quite like One Camelback – we expect this bold development to set a new benchmark for urban elegant living in the Southwest,” said Dale Phillips, President and Founder of Stellar Residential, the management company for One Camelback. “As one of the most ambitious construction transformations ever undertaken in Phoenix, this boutique, Class A development will deliver a vibrant use of residential space, with soaring and dramatic floor-to-ceiling views of Central Phoenix, modern and functional floorplans, upscale amenities and first-class services – all under one 11-story roof, while aesthetically adding some more glamour and elegance to the Phoenix skyline.”
As the iconic landmark undergoes a complete transformation, One Camelback will blend the finest there is in upscale sophisticated living with a range of exclusive, first-to-market retailers in the heart of Central Phoenix. It will be the first 1-Gigabit community, in Arizona through Cox Communications, which means each and every unit will have 1-Gigabit internet speeds included in the rent.
The 215,245-square-foot glass-ensconced property will include 163 first-class apartment units with exposed ceilings and 10 foot floor to ceiling windows. A selection of 16 different floorplans will be available, featuring upscale studio, 1-, 2-, and 3-bedroom apartments, all designed by Erwin Architecture. Additional exclusive residential amenities include a 6,500 square-foot rooftop terrace with a swimming pool, a swim-in place and endless pool for lap swimming or therapy, cabanas and a spa, as well as a yoga lawn deck and a lounge-style clubhouse. Residents will also have access to a secured underground garage with electric car-charging stations.
Capitalizing on its prime location, One Camelback is in negotiations to bring in highly sought-after, first-to-market upscale retailers to blend in with the historic neighborhood’s assortment of hip restaurants and trendy shops. Only walking distance from popular gourmet and specialty grocer AJ’s Fine Foods, One Camelback is also in close proximity to Uptown Plaza and light-rail transportation. The residences and retail spaces will be moments away from the downtown business core, major sporting event arenas, and the popular nightlife scene, serving residents by offering one of the best transit oriented developments known to the Valley.
With more than 143,000 people working within a 3-mile radius of its centralized location, One Camelback is located at the perfect triangle, connecting downtown Phoenix to the Biltmore area.
In March 2019, the construction efforts began with a glass-raising event to celebrate the start of the substantial transformation, from mortar and concrete to dramatic windows and high ceilings that will deliver soaring, bird’s eye views of Central Phoenix. The demolition of interior structures throughout the building was completed earlier this month, leaving a blank canvas for crews to make the vision for this iconic development come to a reality.
One Camelback is being developed by an affiliate of Sagamore Capital LLC, a Scottsdale-based investment firm, with financing arranged by Walker & Dunlop, and provided by Los Angeles-based ACORE Capital LLC. Katerra is acting as general contractor and a prime supplier for the project.
One Camelback is expected to be complete by 2021. More information is available by visiting OneCamelback.com or @LiveOneCamelback on Instagram.
About One Camelback
Situated at the hottest intersection in greater Phoenix, at the southeast corner of Central Ave. & Camelback Road, One Camelback will set a new standard in redefined upscale urban living. With its iconic glass exterior, extravagant residential units and amenities, first-class services and exclusive retail experiences, the boutique Class A development will deliver a highly desirable live-play lifestyle in a building that is expected to help redefine the Phoenix skyline. For more information about One Camelback, visit OneCamelback.com or @LiveOneCamelback on Instagram.
About Sagamore Capital LLC
One Camelback Owner LLC is an affiliate of Sagamore Capital LLC. In addition to One Camelback, Sagamore Capital and its affiliates currently have under development multifamily rental projects in Spokane, Washington, Brooklyn, New York, Jamaica (Queens), New York and Washington D.C., a student housing project in Pullman, Washington and a 14-unit condominium project in the Nolita area of Manhattan. It has been active in the Phoenix area with the successful acquisition and sale of student housing projects and two multifamily projects. Its affiliates are also investors in land developments located in Buckeye and Surprise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom